Quantcast

Latest PDE5 inhibitors Stories

2010-03-19 07:59:00

MOUNTAIN VIEW, Calif., March 19 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Barclays Capital 2010 Global Healthcare Conference. The VIVUS presentation will take place at the Loews Miami Beach Hotel in Miami, FL on Wednesday, March 24, 2010 at 3:15 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS VIVUS...

2010-02-09 07:00:00

CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of...

2010-02-04 06:00:00

MOUNTAIN VIEW, Calif., Feb. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Dr. Charles Bowden, senior director, clinical development, will present an overview of the company at the 12th Annual BIO CEO and Investor Conference. The VIVUS presentation will take place at the Waldorf Astoria Hotel in New York on Tuesday, February 9, 2010 at 10:30 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com or...

ace280b7c7e179fdb9e165b85e95ba9a1
2010-01-12 14:29:31

Biotech firm Vivus revealed a new medication for erectile dysfunction on Monday that may be hitting pharmacy shelves in the near future. The new drug, called avanafil, is said to be effective in just 15 minutes, far faster than big market rivals Cialis and Viagra, according to AFP. Leland Wilson, CEO for Vivus, shined the spotlight on optimistic results for the class three investigational drug to treat male impotency. "The magnitude of success in the first 15 minutes was surprising," he...

2010-01-11 06:00:00

MOUNTAIN VIEW, Calif., Jan. 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED). Patients who attempted intercourse within 15 minutes of dosing were successful 67%, 69% and 72% of the time on 50, 100 and 200 mg of avanafil, respectively, as compared to 29% of the patients on placebo...

2010-01-05 06:00:00

MOUNTAIN VIEW, Calif., Jan. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at the 28th Annual JP Morgan Healthcare Conference. The VIVUS presentation will take place at the Westin St. Francis Hotel in San Francisco, CA on Monday, January 11, 2010 at 8:00 a.m. PT. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS VIVUS is a...

2009-11-18 05:30:00

MOUNTAIN VIEW, Calif., Nov. 18 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients. The REVIVE study met all primary endpoints across the three doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter...

2009-11-17 15:01:00

MOUNTAIN VIEW, Calif., Nov. 17 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m. Eastern time. Conference Call Information Domestic callers: 1-800-776-0853 International callers: 1-913-312-0980 Webcast information: http://ir.vivus.com. A webcast replay will be available on the...

2009-11-11 06:00:00

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Lazard Capital Markets 6th Annual Healthcare Conference. The VIVUS presentation will take place at The St. Regis in New York, NY on Wednesday, November 18, 2009 at 1:45 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS VIVUS is a...

2009-11-05 06:00:00

MOUNTAIN VIEW, Calif., Nov. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at Merriman Curhan Ford's 6th Annual Investor Summit. The VIVUS presentation will take place at the Hotel Sofitel in New York, NY on Tuesday, November 10, 2009 at 8:00 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS VIVUS is a...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related